Balovaptan (RG7314; RG-7314; RO-5285119) is a novel potent and brain-penetrant vasopressin 1a (hV1a) receptor antagonist with the potential to be used for autism. It inhibits hV1a with Kis of 1 and 39 ]nM for human (hV1a) and mouse (mV1a) receptors. Balovaptan has entered phase 3 clinical development in August 2018 [1,2]. However, a recent report showed that balovaptan did not improve socialization and communication difficulties in adults with autism spectrum disorder, according to results of a phase 3 randomized, placebo-controlled, double-blind clinical trial published in Lancet Psychiatry [3]. It has a half-life of 45-47 hours and may be orallly administered once a day [4].

纯度：≥98%

CAS：1228088-30-9